$0.45
(Market cap
$1,591 Mln
Recently Viewed
Clear AllMarket cap
$1,591 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
19.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.8
Debt to Equity
0.1
Book Value
$1.2
EPS
$-1.1
Face value
--
Shares outstanding
67,989,078
CFO
$-250.22 Mln
EBITDA
$-332.15 Mln
Net Profit
$-335.96 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pulse Biosciences Inc (DE) (PLSE)
| 77.9 | 10.5 | 70.1 | 41.3 | 60.4 | 3.6 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Pulse Biosciences Inc (DE) (PLSE)
| -21.1 | 41.8 | 341.9 | -81.3 | -37.9 | 77.9 | 17.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pulse Biosciences Inc (DE) (PLSE)
|
24.4 | 1,590.9 | 0.4 | -72.8 | -6,263.1 | -74.4 | -- | 19.7 |
| 8.3 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 299.5 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.7 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 121.7 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 82.9 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.5 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 332.2 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 124.4 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 | |
| 32.7 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft... tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Read more
Executive Chairman
Mr. Robert W. Duggan
Executive Chairman
Mr. Robert W. Duggan
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Pulse Biosciences Inc (DE) (PLSE) is $24.43 (NASDAQ) as of 22-Apr-2026 16:00 EDT. Pulse Biosciences Inc (DE) (PLSE) has given a return of 60.4% in the last 3 years.
Since, TTM earnings of Pulse Biosciences Inc (DE) (PLSE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-12.64
|
11.41
|
|
2024
|
-18.84
|
8.79
|
|
2023
|
-14.50
|
13.80
|
|
2022
|
-1.60
|
-41.90
|
|
2021
|
-6.57
|
11.62
|
The 52-week high and low of Pulse Biosciences Inc (DE) (PLSE) are Rs 26.30 and Rs 12.56 as of 23-Apr-2026.
Pulse Biosciences Inc (DE) (PLSE) has a market capitalisation of $ 1,591 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Pulse Biosciences Inc (DE) (PLSE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.